Following China approval, FibroGen's anemia drug meets in five additional Phase III trials

FibroGen Inc. (NASDAQ:FGEN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) reiterated plans to submit an NDA to FDA this half for roxadustat to treat anemia in patients

Read the full 250 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE